We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-19.24%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$384M
AUM Growth
-$13.9M
Cap. Flow
+$77.9M
Cap. Flow %
20.3%
Top 10 Hldgs %
46.53%
Holding
98
New
11
Increased
36
Reduced
12
Closed
4

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$24.9M
2
IBB icon
iShares Biotechnology ETF
IBB
+$8.02M
3
FATE icon
Fate Therapeutics
FATE
+$4.99M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$4.59M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$4.37M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$11.1M
2
OTIC
Otonomy, Inc.
OTIC
+$1.49M
3
HOOK
HOOKIPA Pharma
HOOK
+$747K
4
PRQR icon
ProQR Therapeutics
PRQR
+$685K
5
XENE icon
Xenon Pharmaceuticals
XENE
+$674K

Sector Composition

Rank Sector Weight
1 Healthcare 86.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMEA icon
51
Biomea Fusion
BMEA
$91.3M
$1.71M 0.45%
383,923
+70,000
+22% +$454K
RDUS
52
DELISTED
Radius Health, Inc.
RDUS
$1.7M 0.44%
191,978
– –
MGNX icon
53
MacroGenics
MGNX
$257M
$1.69M 0.44%
192,000
+102,000
+113% +$1.13M
COGT icon
54
Cogent Biosciences
COGT
$7.24B
$1.67M 0.44%
223,554
– –
KNTE
55
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$1.67M 0.43%
148,151
+41,698
+39% +$459K
RGLS
56
DELISTED
Regulus Therapeutics
RGLS
$1.66M 0.43%
555,556
– –
NGM
57
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.64M 0.43%
107,653
+27,168
+34% +$424K
IMCR icon
58
Immunocore
IMCR
$1.73B
$1.61M 0.42%
+53,878
New +$1.36M
TPTX
59
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$1.6M 0.42%
59,452
+13,000
+28% +$437K
MRSN
60
DELISTED
Mersana Therapeutics
MRSN
$1.41M 0.37%
14,111
+8,500
+151% +$993K
VERO
61
DELISTED
Venus Concept
VERO
$1.39M 0.36%
5,868
-45
-0.8% -$11.4K
MREO
62
Mereo BioPharma
MREO
$47.3M
$1.36M 0.36%
1,216,613
+90,000
+8% +$116K
VKTX icon
63
Viking Therapeutics
VKTX
$4B
$1.34M 0.35%
447,400
– –
ETNB
64
DELISTED
89bio
ETNB
$1.22M 0.32%
324,053
+179,400
+124% +$1.16M
LITS
65
Lite Strategy Inc
LITS
$30.9M
$1.06M 0.28%
88,357
+115
+0.1% +$4.52K
GHRS icon
66
GH Research
GHRS
$2.08B
$1.01M 0.26%
+55,000
New +$971K
CMPS
67
Compass Pathways
CMPS
$1.83B
$965K 0.25%
+74,890
New +$1.12M
STIM icon
68
Neuronetics
STIM
$166M
$951K 0.25%
313,717
– –
THRX
69
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$924K 0.24%
80,124
-17,376
-18% -$186K
NXTC icon
70
NextCure
NXTC
$23.8M
$912K 0.24%
15,641
– –
BDTX icon
71
Black Diamond Therapeutics
BDTX
$112M
$869K 0.23%
313,600
+107,500
+52% +$392K
WVE icon
72
Wave Life Sciences
WVE
$1.2B
$780K 0.2%
390,161
– –
GNFT
73
DELISTED
Genfit
GNFT
$752K 0.2%
187,940
+127,492
+211% +$521K
ADAP
74
DELISTED
Adaptimmune Therapeutics
ADAP
$723K 0.19%
351,064
+214,798
+158% +$580K
VIGL
75
DELISTED
Vigil Neuroscience
VIGL
$701K 0.18%
+99,754
New +$1.32M
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, DAFNA Capital Management held 98 positions worth $384M, down 3.5% from $398M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

DAFNA Capital Management deployed $77.9M of net new capital in Q1 2022, opening 11 new positions and adding to 36 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 269,500 shares worth $24.2M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 95% a quarter earlier.

On the sell side, the largest reduction was Otonomy, Inc., an estimated $1.49M trimmed.

  • DAFNA Capital Management's largest Q1 2022 buy was State Street SPDR S&P Biotech ETF: 269,500 shares worth $24.2M.
  • DAFNA Capital Management added most to iShares Biotechnology ETF in Q1 2022, an estimated $8.02M increase.
  • DAFNA Capital Management's biggest Q1 2022 reduction was Otonomy, Inc., cutting an estimated $1.49M.
  • DAFNA Capital Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $11.1M.
  • DAFNA Capital Management's ten largest holdings make up 47% of its $384M portfolio in Q1 2022.
  • DAFNA Capital Management opened 11 new positions and closed 4 in Q1 2022.
  • DAFNA Capital Management's portfolio value fell 3.5% quarter-over-quarter to $384M.

Based on DAFNA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.